MICHAEL W ROGERS
CIK 1244159 · See Remarks · last filed 2026-06-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$340.3K
Companies
10
Total Filings
56
Lifetime Open-Market Net
-$405.9K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AKBA | Director | 197,429 | $0.87 | $171.5K | $0 | 9 | 2026-06-22 |
| Aravive, Inc. (ARAV) Delisted | Director | — | $0.04 | — | $0 | 3 | 2022-09-26 |
| EYPT | Director | 11,917 | $14.16 | $168.7K | $0 | 5 | 2019-06-27 |
| Whitehawk Therapeutics, Inc. (ARPO) Delisted | See Remarks | — | $33.00 | — | $0 | 2 | 2019-05-16 |
| KERYX BIOPHARMACEUTICALS INC (KERX) Delisted | Director | 0 | — | — | $0 | 4 | 2018-12-13 |
| EyePoint, Inc. (PSDV) Delisted | Director | — | — | — | $0 | 11 | 2017-12-19 |
| Acorda Therapeutics, Inc. (ACOR) Delisted | Chief Financial Officer | 339 | $0.66 | $224 | -$405.9K | 10 | 2016-05-13 |
| Fortress Biotech, Inc. (CNDO) Delisted | Director | — | — | — | $0 | 2 | 2013-02-11 |
| BG Medicine, Inc. (BGMD) Delisted | EVP, CFO and Treasurer | — | — | — | $0 | 2 | 2012-02-24 |
| IDEV | Executive Vice President | 0 | $93.44 | $0 | $0 | 6 | 2009-02-25 |
Recent Filings · Page 6 of 6
56 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2008-11-20 | EyePoint, Inc. (PSDV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2008-09-29 | IDEV | Grant (A) | +55,918 | $0 | EDGAR |
| 2008-04-15 | IDEV | Mixed | — | $0 | EDGAR |
| 2007-11-29 | EyePoint, Inc. (PSDV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2007-11-01 | IDEV | Grant (A) | +13,500 | $0 | EDGAR |
| 2007-04-11 | IDEV | Mixed | — | $0 | EDGAR |
Showing 51–56 of 56
Prev
Page 6 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.